Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

Exclusion Criteria

• •Patients with any of the following conditions will not be included in the study:
• •1. History of allogeneic hematopoietic stem cell transplantation.
• •2. History of epilepsy, cerebrovascular ischemia/bleeding, dementia, cerebellar disease, or any autoimmune disease involving the central nervous system.
• •3. Any other malignancies within the past 2 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors (Ta, Tis, and T1).
• •4. Severe cardiovascular disease: NYHA grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias; NYHA grade III to IV heart failure or left ventricular ejection fraction (LVEF) \< 50%.
• •5. Allergy to any investigational drug or excipient.
• •6. Active viral hepatitis requiring treatment, including chronic HBV carriers with HBV DNA ≥ 500 IU/mL and positive HCV RNA.
• •7. Active autoimmune disease or known history of allogeneic organ transplantation; long-term heavy use of immunosuppressants or other factors affecting study therapy.
• •8. Active infection.
• •9. History of uncontrolled systemic disease, such as diabetes or hypertension.
• •10. Known HIV infection.
• •11. Underlying medical condition or substance abuse that may interfere with drug administration or affect result interpretation, or increase treatment risk.
• •12. End-organ damage from autoimmune disease within the past 2 years or systemic use of immunosuppressive drugs.